Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer

Journal of Surgical Oncology

Volumn 106, Issue 7, 2012, Pages 887-891

  Ishizuka, Mitsuru ^a   Nagata, Hitoshi ^a   Takagi, Kazutoshi ^a   Iwasaki, Yoshimi ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

colorectal cancer; survival after surgery; systemic inflammatory response; thrombocytosis

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 84868384472     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23163     Document Type: Article

References (48)

1. McMillan DC, Canna K, McArdle CS,: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-219.
2. Ishizuka M, Nagata H, Takagi K, et al.: Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 2007; 246: 1047-1051.
3. Ramsey S, Lamb GW, Aitchison M, et al.: Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-212.
4. Forrest LM, McMillan DC, McArdle CS, et al.: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004; 90: 1704-1706.
5. Canna K, McArdle PA, McMillan DC, et al.: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92: 651-654.
6. Ohsugi Y,: Recent advances in immunopathophysiology of interleukin-6: An innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007; 30: 2001-2006.
7. Ramadori G, Van Damme J, Rieder H, et al.: Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988; 18: 1259-1264.
8. Vermeire S, Van Assche G, Rutgeerts P,: The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 580-586.
9. Miki C, Konishi N, Ojima E, et al.: C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 2004; 49: 970-976.
10. Ruscetti FW,: Hematologic effects of interleukin-1 and interleukin-6. Curr Opin Hematol 1994; 1: 210-215.
11. Imai T, Koike K, Kubo T, et al.: Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 1991; 78: 1969-1974.
12. Shimada H, Takiguchi N, Kainuma O, et al.: High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13: 170-176.
13. Azab B, Bhatt VR, Phookan J, et al.: Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 2012; 19: 217-224.
14. Kaser A, Brandacher G, Steurer W, et al.: Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
15. Nakano T, Chahinian AP, Shinjo M, et al.: Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998; 77: 907-912.
16. Nyasavajjala SM, Runau F, Datta S, et al.: Is there a role for pre-operative thrombocytosis in the management of colorectal cancer? Int J Surg 2010; 8: 436-438.
17. Monreal M, Fernandez-Llamazares J, Pinol M, et al.: Platelet count and survival in patients with colorectal cancer-A preliminary study. Thromb Haemost 1998; 79: 916-918.
18. Aminian A, Karimian F, Mirsharifi R, et al.: Significance of platelet count in esophageal carcinomas. Saudi J Gastroenterol 2011; 17: 134-137.
19. Jain S, Harris J, Ware J,: Platelets: Linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30: 2362-2367.
20. Stone RL, Nick AM, McNeish IA, et al.: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-618.
21. Youden WJ,: Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
22. Brown KM, Domin C, Aranha GV, et al.: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005; 189: 278-282.
23. Dajani K, O'Reilly DA, Carino NL, et al.: The prognostic significance of the preoperative full blood count after resection of colorectal liver metastases. HPB Surg 2009; 2009: 425065.
24. Symbas NP, Townsend MF, El-Galley R, et al.: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-207.
25. Gorelick C, Andikyan V, Mack M, et al.: Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population. Int J Gynecol Cancer 2009; 19: 1384-1389.
26. Shimada H, Oohira G, Okazumi S, et al.: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
27. Lavie O, Comerci G, Daras V, et al.: Thrombocytosis in women with vulvar carcinoma. Gynecol Oncol 1999; 72: 82-86.
28. Gislason T, Nou E,: Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: An epidemiological study. Eur J Respir Dis 1985; 66: 141-146.
29. Silvis SE, Turkbas N, Doscherholmen A,: Thrombocytosis in patients with lung cancer. JAMA 1970; 211: 1852-1853.
30. Hefler L, Mayerhofer K, Leibman B, et al.: Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol 2000; 21: 309-314.
31. Hernandez E, Lavine M, Dunton CJ, et al.: Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-2977.
32. Pedersen LM, Milman N,: Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9: 1826-1830.
33. Troxler M, Dickinson K, Homer-Vanniasinkam S,: Platelet function and antiplatelet therapy. Br J Surg 2007; 94: 674-682.
34. Jurasz P, Alonso-Escolano D, Radomski MW,: Platelet-cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819-826.
35. Roxburgh CS, Wallace AM, Guthrie GK, et al.: Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative surgery for colon cancer. Colorectal Dis 2010; 12: 987-994.
36. Kandemir EG, Mayadagli A, Karagoz B, et al.: Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res 2005; 33: 228-235.
37. Klinger MH,: Platelets and inflammation. Anat Embryol (Berl) 1997; 196: 1-11.
38. Mohle R, Green D, Moore MA, et al.: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-668.
39. Pinedo HM, Verheul HM, D'Amato RJ, et al.: Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
40. Browder T, Folkman J, Pirie-Shepherd S,: The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-1524.
41. Takahashi Y, Bucana CD, Akagi Y, et al.: Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998; 4: 429-434.
42. George ML, Eccles SA, Tutton MG, et al.: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147-3152.
43. Gunsilius E, Petzer A, Stockhammer G, et al.: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-174.
44. Ferrara N,: Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1-30.
45. Sierko E, Wojtukiewicz MZ,: Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108.
46. Khorana AA, Fine RL,: Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5: 655-663.
47. Engel CJ, Bennett ST, Chambers AF, et al.: Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996; 20: 1260-1265.
48. Tan TT, Coussens LM,: Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007; 19: 209-216.